tbuckley/cabot-search huggingface dataset:
Abstract 3330: Effect of Achieved Low-density Lipoprotein Cholesterol Level by Atorvastatin on Stabilization of Coronary Plaques - Results from TWINS study
Authors: Katsuki Okada, Yasunori Ueda, Satoshi Saito, Atsushi Hirayama, Kazuhisa Kodama
Journal: Circulation (2007)

Background We have previously reported the stabilization and regression of coronary plaque by atorvastatin using both angioscopy and IVUS. However, it has not been clarified if plaque stabilization is achieved through the reduction of cholesterol level or the direct effect of statin. Then, we analyzed the effect of achieved low-density lipoprotein (LDL) cholesterol level on the stabilization of coronary plaque. Methods Twenty-nine patients with hypercholesterolemia and coronary heart disease were studied. They received lipid-lowering therapy with atorvastatin (10 –20 mg/day) for 80 weeks and were divided into 2 groups by the achieved LDL cholesterol level at 80-week follow up (low LDL group: LDL cholesterol &lt; median value, and high LDL group: LDL cholesterol ≥ median value). Angioscopic examination was performed before and after 80 weeks treatment with atorvastatin. Angioscopic findings of coronary yellow plaque characteristics were divided into six grades (grade 0 to 5) to evaluate vulnerability of plaques; and the mean grade of each patient was evaluated. Results In all 29 patients, LDL cholesterol level was reduced (146.2 to 87.9 mg/dl; p&lt;0.001) and the mean yellow plaque grade was decreased (1.4 to 1.2; p=0.002) at 80-week follow up. LDL cholesterol level was reduced both in low LDL group (140.3 to 75.9 mg/dl; p&lt;0.001) and in high LDL group (151.7 to 99.1 mg/dl; p&lt;0.001). Angioscopic examination showed significant improvement of the grade in low LDL group (1.4 to 1.1; p=0.012) at 80-week follow up, but no significant difference in high LDL group (1.4 to 1.3; p=0.11). Conclusions Lipid-lowering therapy with atorvastatin stabilized coronary plaques, and this effect was larger in the patients LDL cholesterol was reduced more.
Allogeneic stem cell transplantation in patients with Hodgkin's-Lymphoma
Authors: H. Pohl, A. Shimoni, N. Kroeger, H. Martin, V. Vucinic, N. Basara, A. Nagler, A. Zander, A. A. Fauser, M. G. Kiehl
Journal: Journal of Clinical Oncology (2004)

6690 Background: Due to intensified standard radio-chemotherapy a substantial proportion of patients will be cured of Hodgkin's Lymphoma. In patients with relapse after standard therapy, the therapy of choice is an autologous stem cell transplantation with high remission rates. Despite therapeutic progress some patients suffer from refractory or relapsing disease. As graft versus Hodgkin's lymphoma effects have been described allready, allogeneic stem cell transplantation might be an therapeutic effort in these high risk patients. Methods: We analysed the course of 14 patients receiving an allogeneic transplant between 07/99 and 11/03. Results: Median age was 23 years (range 19 to 41) and patients received a median of 4.5 chemotherapies (range 2 to 8) before transplant. All but one received previously an autologous transplant. Disease status at transplant was CR in 2, PR in 1, SD in 5, and PD in 6 patients. Eight patients received a transplant from a related HLA-identical donor and 6 from an unrelated donor (4 matched, 2 DRB1 mismatch). All but one received peripheral blood stem cell grafts. Different conditioning regimens were used (Fludarabine (Flu)/busulfan (Bu) "b ATG n=6, Flu/Melphalan (Mel) "b Campath n=5, Bu/Cy n=1, TBI/Cy n=1, Mel/Thiotepa/ATG n=1). Four patients received donor lymphocyte infusions in escalating dosage for SD (n=2), PD (n=1), or mixed chimerism (n=1), respectively. OS is 43% and DFS 28.6% after a median FU of 25 months (1 to 52 months). TRM is 14.3 %. Five patients died due to disease progression and one due to refractory GVHD. Conclusions: Taking into account that all patients were heavily pre-treated and that only two patients were transplanted in CR these data argue for a strong graft versus Hodgkin effect. Especially a melphalan/fludarabin "b ATG reduced conditioning seems to be very effective in this setting. Furthermore, it's speculative but very likely that the results of allogeneic stem cell transplantation will improve significantly if patients receive the allo transplant earlier during their disease. Thus, risk factors should be defined and those patients with a high risk feature should be scheduled for allo transplant within a controlled clinical trial. No significant financial relationships to disclose.
As immune system yields its secrets, new strategies against disease emerge
Authors: C. Marwick
Journal: JAMA (1989)

KNOWLEDGE of the immune system and ways in which it might be manipulated, gained during the last 10 years, is beginning to have an impact on clinical medicine. That message has emerged from the annual meeting of the Institute of Medicine, Washington, DC. It was enunciated specifically by Hugh McDevitt, MD, Stanford (Calif) University School of Medicine, who chaired the meeting. Until a few years ago, immune cell-secreted cytokines such as the interleukins and lymphokines were laboratory curiosities—tools for the scientists investigating the immune system. But now they have been cloned and, by means of recombinant DNA techniques, are available in quantity. This means that the role of these growth factors in mediating the immune response can now be studied. <h3>Looking to Interleukins</h3> As an example of what is being learned, William E. Paul, MD, says, one of these interleukin messengers between leukocytes, interleukin 4 (IL-4), is now recognized as
Outbreak of Type E Botulism Associated With an Uneviscerated, Salt-Cured Fish Product—New Jersey, 1992
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fasting hypoglycemia secondary to disopyramide therapy. Report of two cases
Authors: S. F. Quevedo
Journal: JAMA (1981)

THE ANTIARRHYTHMIC drug, disopyramide phosphate, has been available for several years and recently has gained increasing acceptance as a second-line antiarrhythmic agent. During many years of use in Europe, the most common side effects have been related to anticholinergic properties. Recently, a case of disopyramide-induced fasting hypoglycemia was reported.<sup>1</sup>This association had not been previously noted in the literature, although a brief reference to hypoglycemia is mentioned in the 1980<i>Physicians' Desk Reference</i>.<sup>2</sup>We report two recent cases of apparent disopyramide-associated fasting hypoglycemia. <h3>Report of Cases</h3><h3>Case 1.—</h3> A 72-year-old woman was admitted to Miriam Hospital, Providence, RI, in June 1980 with an acute myocardial infarction. She had previously had slightly elevated fasting glucose values. Fasting glucose levels were 113 and 154 mg/dL. Intravenous (IV) lidocaine hydrochloride therapy was begun, followed by oral disopyramide phosphate therapy, 150 mg every six hours, because of failure to control recurrent ventricular
index to advertisers
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
Authors: Dimitris Varvaki Rados, Lana Catani Pinto, Luciana Reck Remonti, Cristiane Bauermann Leitão, Jorge Luiz Gross
Journal: PLoS Medicine (2016)

[This corrects the article DOI: 10.1371/journal.pmed.1001992.].
Cell biology/cytokines
Journal: Gut (1994)

was observed only in the FK506 group.Under CsA, low IL-5 mRNA levels were detected in both AR (39%) and NRI (34%) biopsies.Conclusion: IL-2 and IL4 are overexpressed during acute rejection under both CsA and FK-506 immunosuppression.FK506 treatment is associated with an enhanced TNFa expression, and in contrast to CsA an increased IL-S gene activity during AR.These data show differential in situ effects of CsA and FK506 on cytokine gene activation during acute hepatic allograft rejection.
The Avalanche.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SHOULD SYPHILITIC MEDICAL MEN CONTINUE IN PRACTICE?
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Authors: S. J. LEGRUE
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article BOOK REVIEWS Get access Immune Responses to Metastases, Vol. I and Vol. II. R. B. Herberman, R. H. Wiltrout, E. Gorelik, eds. Boca Raton, FL: CRC Press, 1987, 119 pp. (vol.I) and 139 pp. (vol. II). $175.00 (U.S.) and $200.00 (foreign). STEPHEN J. LEGRUE STEPHEN J. LEGRUE Department of Immunology, University of Texas, M. D. Anderson Cancer Center1515 Holcombe Blvd Houston, TX 77030 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 19, 7 December 1988, Page 1572, https://doi.org/10.1093/jnci/80.19.1572 Published: 07 December 1988
In-flight deaths during commercial air travel. How big is the problem?
Authors: R. O. Cummins
Journal: JAMA (1988)

Do passenger deaths occur during commercial air travel? If so, how often and from what causes? We reviewed information reported to the International Air Transport Association on in-flight deaths that occurred during commercial air travel for the eight years between 1977 and 1984. Of the 120 airlines in the International Air Transport Association, 42 carriers reported deaths during these eight years. A total of 577 in-flight deaths were recorded, for a reported average of 72 deaths per year. Deaths occurred at average rates of 0.31 per million passengers, 125 per billion passenger-kilometers, and 25.1 per million departures. The majority of those who died were men (66%, 382/577) and middle-aged (mean age, 53.8 years). Most of the individuals (77%, 399/515) reported no health problems prior to travel. Physicians aboard the aircrafts offered medical assistance for 43% (247/577) of the deaths. More than half of the deaths (56%, 326/577) seemed to be related to cardiac problems. Sudden unexpected cardiac death was the cause of death in 63% (253/399) of the apparently healthy people and seems to be the major cause of death during air travel. These observations support the initiation of programs to train cabin personnel in the skills of basic cardiopulmonary resuscitation and in the use of automatic external defibrillators. (<i>JAMA</i>1988;259:1983-1988)
Pregnancy Termination and Risk of Breast Cancer
Authors: Stanley K. Henshaw
Journal: JAMA (1996)

<h3>To the Editor.</h3> —In their article on the association between breast cancer and abortion, Dr Newcomb and colleagues<sup>1</sup>indicated awareness of the existence of underreporting of induced abortion in retrospective studies and of the possibility that women who have breast cancer might be more accurate in reporting their abortion histories than women who do not have cancer. However, the underreporting of induced abortion in their study may have been greater than they realized. Using data collected by the Alan Guttmacher Institute<sup>2</sup>and the Centers for Disease Control and Prevention,<sup>3</sup>we estimate that 25% of females aged 15 through 44 years in 1989 had 1 or more induced abortions at sometime in their life. Although this percentage varies with age, it is a reasonable estimate for women younger than 45 years in the study by Newcomb et al. For women aged 45 years and older, most of whose
101 Cases of Exfoliative Dermatitis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
APACHE scores
Authors: J. D. Klein
Journal: JAMA (1991)

<h3>In Reply.—</h3> Dr Uhlich thoughtfully touches on a complex question known in Germany as the "historians' conflict" (<i>Historikerstreit</i>).<sup>1</sup>Namely, was the Holocaust unique among mass killings committed throughout history, or was it comparable to other national horrors (like African slavery or Stalin's purges)? Other troublesome questions follow from this one. If the mechanized extermination of nearly 6 million Jews by the Nazis is regarded as uniquely evil among genocides, then does this imply that the German "national character" is inherently flawed? Are Germans by their nature prone to committing heinous acts? Or, in a different vein, if we regard Auschwitz as just another example, among many, of man's inhumanity to man, are we thereby engaging in a form of Holocaust "revisionism" that attempts to exonerate the German people of a guilty sentence they rightly deserve? These difficult questions do not lend themselves to simple answers. My own opinions have
Large medicaid practices and medicaid mills
Authors: J. B. Mitchell
Journal: JAMA (1980)

There is growing concern that large Medicaid practices (LMPs) may be "Medicaid mills" in which low-quality care is provided. Based on survey data, this study sought to determine whether physicians who treat a disproportionate number of Medicaid patients are in fact operating mills. While practices with at least 30% Medicaid patients are a minority of all practices (15.8%), nearly 60% of all Medicaid patients receive care there. There is no evidence that LMPs can be characterized as Medicaid mills. Visit lengths are shorter in LMPs, but only by two minutes. Nor is there any widespread abuse of ancillary services, skimping on auxiliary staff, or excessive incomes. The LMP physicians, however, do tend to be older, to be trained in foreign medical schools, and to have fewer credentials, such as board certification. (<i>JAMA</i>244:2433-2437, 1980)
GSK3β regulates physiological migration of stem/progenitor cells via cytoskeletal rearrangement
Authors: Kfir Lapid, Tomer Itkin, Gabriele D’Uva, Yossi Ovadya, Aya Ludin, Giulia Caglio, Alexander Kalinkovich, Karin Golan, Ziv Porat, Massimo Zollo, Tsvee Lapidot
Journal: Journal of Clinical Investigation (2013)
Prostate Cancer
Authors: Lalit R. Patel
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"THE SCIENTIFIC MOTIVE."
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Infectious Diseases Update: Outbreak, Hantavirus Infection—Southwestern United States, 1993
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal